A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS
Status:
COMPLETED
Trial end date:
2025-08-22
Target enrollment:
Participant gender:
Summary
This Phase 1 randomized, placebo-controlled, double-blind study will evaluate the PK/PD relationship of single doses of QRL-101 in 12 ALS participants. The study will also assess safety and tolerability in participants receiving either QRL-101 or placebo.